AstraZeneca’s (AZN) Sell Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reissued their sell rating on shares of AstraZeneca (LON:AZN) in a report released on Wednesday morning,Digital Look reports. They currently have a £115 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on the company. Citigroup boosted their price target on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a report on Friday, April 10th. Shore Capital Group reaffirmed a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research report on Thursday, January 15th. Berenberg Bank upped their price target on AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a £180 price target on shares of AstraZeneca in a research report on Friday, April 10th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of £153.33.

AstraZeneca Price Performance

Shares of LON AZN opened at £133.44 on Wednesday. The stock has a market capitalization of £206.95 billion, a PE ratio of 20.10, a P/E/G ratio of 0.86 and a beta of 0.22. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59. The business has a fifty day moving average price of £145.54 and a two-hundred day moving average price of £140.07. AstraZeneca has a fifty-two week low of GBX 9,651 and a fifty-two week high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.